The 4 most recent market catalysts affecting $BIO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390
RBC Capital's analyst Dan Leonard has maintained an 'Outperform' rating on Bio-Rad Laboratories and raised the price target from $370 to $390. This action signals a positive outloo…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370
RBC Capital's analyst Dan Leonard has maintained an 'Outperform' rating on Bio-Rad Laboratories (BIO) and raised the price target from $320 to $370. This action signals increased c…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
Bio-Rad Laboratories Lowers FY2026 Sales Guidance of $2.506B-$2.596B vs $2.567B Est
Bio-Rad Laboratories (BIO) has announced a reduction in its sales guidance for fiscal year 2026. The new range of $2.506 billion-$2.596 billion, while seemingly the same as the pre…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 92
Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M Estimate
Bio-Rad Laboratories announced Q2 adjusted EPS of $2.62, significantly surpassing the analyst consensus of $1.75, a beat of nearly 50%. Sales also exceeded expectations at $651 mil…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.